Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914 24. 186. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoi- etins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708 14. 187. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoe- tin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019 32. 188. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791 8. 189. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. 190. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less inten- sive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613 22. 191. Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103 16. 192. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs stan- dard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: A randomized clinical trial. JAMA. 2016;315:2673 82. 193. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic re- view and meta-analysis. CMAJ. 2013;185:949 57. 194. Deleted in press. 195. Aronow WS, Fleg JL, Pepine CJ, et al. 